Experimental therapies using nanoparticles: nanomaterials in triple-negative breast cancer (TNBC) treatment

Feret, Wiktoria

doi:10.21164/pomjlifesci.792

Abstract

Triple-negative breast cancer (TNBC) accounts for approx. 10–20% of breast cancer diagnoses worldwide. Triple-negative breast cancer cells have no estrogen nor progesterone receptors and lack overexpression of human epidermal growth factor receptor. As no hormone therapy can be implemented, chemotherapy remains the main weapon. Nowadays, widely available chemo regimens for TNBC treatment can consist of anthracyclines, taxanes, antimetabolites, or platinums, but all of the aforementioned are highly toxic to the bone marrow, liver, kidneys, and nervous system. Targeted treatment using nanotechnology seems to be a ray of hope in impeding this morbid disease.

References

1. Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J 2021;27(1):8-16. doi: 10.1097/PPO.0000000000000500.10.1097/PPO.000000000000050033475288
Search in Google Scholar Back to article
2. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23 Suppl 6:vi7-12. doi: 10.1093/annonc/mds187.10.1093/annonc/mds18723012306
Search in Google Scholar Back to article
3. Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol 2021;7(7):1016-23. doi: 10.1001/jamaoncol.2021.1254.10.1001/jamaoncol.2021.1254812044133983438
Search in Google Scholar Back to article
4. Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel) 2020;12(9):2392. doi: 10.3390/cancers12092392.10.3390/cancers12092392756556632846967
Search in Google Scholar Back to article
5. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target 2016;24(3):179-91. doi: 10.3109/1061186X.2015.1051049.10.3109/1061186X.2015.105104926061298
Search in Google Scholar Back to article
6. Lungu II, Grumezescu AM, Volceanov A, Andronescu E. Nanobiomaterials used in cancer therapy: an up-to-date overview. Molecules 2019;24(19):3547. doi: 10.3390/molecules24193547.10.3390/molecules24193547680409131574993
Search in Google Scholar Back to article
7. Saraiva SM, Gutiérrez-Lovera C, Martínez-Val J, Lores S, Bouzo BL, Díez-Villares S, et al. Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model. Sci Rep 2021;11(1):9873. doi: 10.1038/s41598-021-87968-4.10.1038/s41598-021-87968-4811099533972572
Search in Google Scholar Back to article
8. Lasa-Saracíbar B, Aznar MÁ, Lana H, Aizpún I, Gil AG, Blanco-Prieto MJ. Lipid nanoparticles protect from edelfosine toxicity in vivo. Int J Pharm 2014;474(1-2):1-5. doi: 10.1016/j.ijpharm.2014.07.053.10.1016/j.ijpharm.2014.07.05325091376
Search in Google Scholar Back to article
9. Luo W, Wang Y. Hypoxia mediates tumor malignancy and therapy resistance. Adv Exp Med Biol 2019;1136:1-18. doi: 10.1007/978-3-030-12734-3_1.10.1007/978-3-030-12734-3_131201713
Search in Google Scholar Back to article
10. Cheng FY, Chan CH, Wang BJ, Yeh YL, Wang YJ, Chiu HW. The oxygen-generating calcium peroxide-modified magnetic nanoparticles attenuate hypoxia-induced chemoresistance in triple-negative breast cancer. Cancers (Basel) 2021;13(4):606. doi: 10.3390/cancers13040606.10.3390/cancers13040606791361933546453
Search in Google Scholar Back to article
11. Verry C, Porcel E, Chargari C, Rodriguez-Lafrasse C, Balosso J. Utilisation de nanoparticules comme agent radiosensibilisant en radiothérapie: où en est-on? Cancer Radiother 2019;23(8):917-21. doi: 10.1016/j.canrad.2019.07.134.10.1016/j.canrad.2019.07.13431540838
Search in Google Scholar Back to article
12. Her S, Jaffray DA, Allen C. Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements. Adv Drug Deliv Rev 2017;109:84-101. doi: 10.1016/j.addr.2015.12.012.10.1016/j.addr.2015.12.01226712711
Search in Google Scholar Back to article
13. Janic B, Brown SL, Neff R, Liu F, Mao G, Chen Y, et al. Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer. Cancer Biol Ther 2021;22(2):124-35. doi: 10.1080/15384047.2020.1861923.10.1080/15384047.2020.1861923792801633459132
Search in Google Scholar Back to article
14. Simons M, Raposo G. Exosomes – vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009;21(4):575-81. doi:10.1016/j.ceb.2009.03.007.10.1016/j.ceb.2009.03.00719442504
Search in Google Scholar Back to article
15. Zhou X, Xie F, Wang L, Zhang L, Zhang S, Fang M, et al. The function and clinical application of extracellular vesicles in innate immune regulation. Cell Mol Immunol 2020;17(4):323-34. doi: 10.1038/s41423-020-0391-1.10.1038/s41423-020-0391-1710910632203193
Search in Google Scholar Back to article
16. Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci 2019;110(10):3173-82. doi: 10.1111/cas.14181.10.1111/cas.14181677863831464035
Search in Google Scholar Back to article

Experimental therapies using nanoparticles: nanomaterials in triple-negative breast cancer (TNBC) treatment

Abstract

Paradigm

My account